Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D. For around a quarter of a century now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’ll look at how the land lies at the start of 2017. We’ll assess industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects, which has been tracking global drug development since 1980. This report will be followed up by our annual supplement reviewing the New Active Substance launches for the year just past. But here, we will be focusing on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016.